Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$11.87M$11.87Mderived−10.1% vs Q4 2023 Net Income-$17.06M-$17.06MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$13,579,000N/M Operating Cash Flowderived-$6,489,000N/M Free Cash Flowderived-$6,504,000N/M Margins · derivedOperating margin-114.4%−84.8 pt vs Q4 2023
Net margin-143.7%−82.3 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 5, 2025 · 64 d after period end